$NEXI News

Last published 2y ago

2y agoNEXINexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireGAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of
2y agoNEXINexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireGAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of
3y agoNEXINexImmune, Yale, and JDRF Extend Research Partnership for Type 1 DiabetesGlobeNewswireA JDRF funded grant is being used to explore the combination of NexImmune's antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE
3y agoNEXINexImmune Announces Presentations at The Society for Immunotherapy of Cancer's 38th Annual MeetingGlobeNewswireGAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of
3y agoNEXINexImmune Announces 1-for-25 Reverse Stock SplitGlobeNewswireGAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI) (the "Company") a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response
3y agoNEXINexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development StrategyGlobeNewswireCompany retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE
3y agoNEXINexImmune Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswireNEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments;
3y agoNEXINexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual MeetingGlobeNewswire- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related
3y agoNEXINexImmune Announces Poster Presentation at the 2023 FOCIS Annual MeetingGlobeNewswireAIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease Data suggests a
3y agoNEXINexImmune Reports First Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswireCompany has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc.
3y agoNEXINexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual MeetingGlobeNewswireGAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing
3y agoNEXINexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewswireCompany has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to follow patients and
3y agoNEXINexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewswireTumor Associated Antigen (TAA)-specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naïve CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in vivo GAITHERSBURG,
3y agoNEXINexImmune Announces Publication in Frontiers in Medicine Highlighting the Company's AIM Platform to Treat Viral DiseasesGlobeNewswireAIM technology represents a scalable therapeutic platform that has the potential to create new, multi-antigen specific therapies for virally driven infectious diseases, cancers and autoimmune diseases GAITHERSBURG,
3y agoNEXINexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic UpdateGlobeNewswireCompany announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseasesInitiating a corporate resource reallocation to
4y agoNEXINexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)GlobeNewswireGAITHERSBURG, Md., Oct. 06, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
4y agoNEXINexImmune to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireGAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of an
4y agoNEXISelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune DisordersBusiness WireAgreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options f
4y agoNEXINexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related CancersGlobeNewswireReceived U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancers Plans to report additional preclinical and
4y agoNEXINexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related CancersGlobeNewswireFirst IND for NexImmune's AIM nanoparticle platform in solid tumors IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human pa
4y agoNEXINexImmune Reports First Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewswireClinical data updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 2H2022 Investigational New Drug (IND) submission for NEXI-003, the Company's first product for solid tumors, planned for 1H2022 Plans to repor
4y agoNEXINexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 DiabetesGlobeNewswireA JDRF funded grant will be used to explore the combination of NexImmune's antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc.�
4y agoNEXINexImmune Announces Appointment of Dr. Leena Gandhi to its Board of DirectorsGlobeNewswireGAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of anti
4y agoNEXINexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer CenterGlobeNewswireGAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of an
4y agoNEXINexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific OfficerGlobeNewswireGAITHERSBURG, Md., April 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of an
4y agoDNA HYMC LBPS NEXI+1Thinking about buying stock in Hycroft Mining, Nielsen, Neximmune, 4D pharma, or Ginkgo Bioworks?PR NewswireNEW YORK, March 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, NLSN, NEXI, LBPS, and DNA.
4y agoNEXINexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and ValidationGlobeNewswireGAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology.
4y agoNEXINexImmune Announces Melanoma Research Collaboration with NYU Langone's Perlmutter Cancer CenterGlobeNewswireGAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
4y agoNEXINexImmune to Present at the Barclays 2022 Global Healthcare ConferenceGlobeNewswireGAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of an
4y agoNEXINexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatesGlobeNewswireClinical data updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 2H22 Investigational New Drug (IND) submission for NEXI-003, the Company's first product for solid tumors, planned for 1H22 Plans to report ad
4y agoNEXINexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of DirectorsGlobeNewswireGAITHERSBURG, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
4y agoNEXINexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor TargetsGlobeNewswireGAITHERSBURG, Md., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
4y agoNEXINexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on "Expanding the Possible with Next-Generation Cell Therapies"GlobeNewswireGAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
4y agoNEXINexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory BoardGlobeNewswireGAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
4y agoNEXINexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple MyelomaGlobeNewswireInitial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition Phase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory multiple myeloma patients who have failed ≥3 prior lines
5y agoNEXINexImmune Reports Third Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireAdvancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022 Announced collaboration with Yale University Department of Immunobiology to explore use of AI
5y agoNEXINexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021GlobeNewswireGAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
5y agoNEXINexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual MeetingGlobeNewswireGAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
5y agoNEXINexImmune to Present at the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewswireGAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of an
5y agoNEXINexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewswireGAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of an
5y agoNEXINexImmune Reports Second Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireAnnouncing first solid tumor indication in HPV associated-malignancies – NEXI-003 Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated in the second half of 2021
5y agoNEXINexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 DiabetesGlobeNewswireGAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
5y agoNEXINexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021GlobeNewswireGAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
5y agoNEXINexImmune Strengthens Management Team with Key AppointmentsGlobeNewswireDr. Jack A. Ragheb as Senior Vice President, Translational Science Matt Schiller, Head of Business Development GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing
5y agoNEXINexImmune to Present at the Raymond James 2021 Human Health Innovation ConferenceGlobeNewswireGAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of ant
5y agoNEXINexImmune Announces Formation of Scientific Advisory BoardGlobeNewswireGAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of anti
5y agoNEXINexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual MeetingGlobeNewswireGAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of anti
5y agoNEXINexImmune Reports First Quarter 2021 Financial Results and Recent UpdatesGlobeNewswireAdvancing two lead product candidates in Phase 1/2 clinical trials Completed successful $126M initial public offering (IPO) in February 2021 Additional clinical and preclinical data anticipated in the second half of 2021 GAITHERSBURG, Md., May
5y agoNEXINexImmune Appoints Chad Rubin as Senior Vice President, Corporate AffairsGlobeNewswireMr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel appro
5y agoNEXINexImmune Reports Fiscal Year 2020 Financial Results and Recent UpdatesGlobeNewswireIn 2020, advanced two product candidates into Phase 1/2 clinical trials while strengthening Board of Directors and management teamCompleted successful $126M initial public offering (IPO) in February...